Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines

Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129 · see citing works

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · see citing works

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali‐Krishna, K. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050821 · Cited by 967 · see citing works

Germinal centres: role in B-cell physiology and malignancy

Klein, U., & Dalla‐Favera, R. (2007) · Nature reviews. Immunology · doi:10.1038/nri2217 · Cited by 899 · see citing works

Innate Recognition of Viruses

Pichlmair, A., & Sousa, C. R. E. (2007) · Immunity · doi:10.1016/j.immuni.2007.08.012 · Cited by 690 · see citing works

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant

Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M. F., de Matos, I. G., Kluger, C., Salazar, A. Μ., Colonna, M., & Steinman, R. M. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663 · see citing works

The perfect mix: recent progress in adjuvant research

Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 621 · see citing works

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.

Brinkmann, V., Geiger, T. M., Alkan, Ş. Ş., & Heusser, C. H. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.178.5.1655 · Cited by 505 · see citing works

Induction of virus‐specific cytotoxic T lymphocytes <i>in vivo</i> by liposome‐entrapped mRNA

Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473 · see citing works

Diversity in T Cell Memory: An Embarrassment of Riches

Jameson, S. C., & Masopust, D. (2009) · Immunity · doi:10.1016/j.immuni.2009.11.007 · Cited by 382 · see citing works

Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses

Nakano, H., Lin, K. L., Yanagita, M., Charbonneau, C., Cook, D. N., Kakiuchi, T., & Gunn, M. D. (2009) · Nature Immunology · doi:10.1038/ni.1707 · Cited by 341 · see citing works

Untitled work

(1995) · PubMed · Cited by 330 · see citing works

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309 · see citing works

Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming

Bon, A. L., Durand, V., Kamphuis, E., Thompson, C., Bulfone‐Paus, S., Rossmann, C., Kalinke, U., & Tough, D. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4682 · Cited by 283 · see citing works

Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells

Bettinger, T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.18.3882 · Cited by 224 · see citing works

Cutting Edge: The Direct Action of Type I IFN on CD4 T Cells Is Critical for Sustaining Clonal Expansion in Response to a Viral but Not a Bacterial Infection

Havenar‐Daughton, C., Kolumam, G. A., & Murali‐Krishna, K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3315 · Cited by 211 · see citing works

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy

Lint, S. V., Goyvaerts, C., Maenhout, S. K., Goethals, L., Disy, A., Benteyn, D., Pen, J. J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210 · see citing works

Designing polymeric particles for antigen delivery

Koker, S. D., Lambrecht, B. N., Willart, M. A. M., van Kooyk, Y., Grooten, J., Vervaet, C., Remon, J. P., & Geest, B. G. D. (2010) · Chemical Society Reviews · doi:10.1039/b914943k · Cited by 147 · see citing works

Induction of type I interferon by RNA viruses: cellular receptors and their substrates

Baum, A., & García‐Sastre, A. (2009) · Amino Acids · doi:10.1007/s00726-009-0374-0 · Cited by 141 · see citing works

Vaccination with Messenger RNA (mRNA)

Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126 · see citing works

Tumor vaccination using messenger RNA: prospects of a future therapy

Kreiter, S., Diken, M., Selmi, A., Türeci, Ö., & Şahin, U. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.007 · Cited by 120 · see citing works

Nonviral Approach for Targeted Nucleic Acid Delivery

Jafari, M., Soltani, M., Naahidi, S., Karunaratne, D. N., & Chen, P. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803414141 · Cited by 119 · see citing works

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

Rajagopal, D., Paturel, C., Morel, Y., Uematsu, S., Akira, S., & Diebold, S. S. (2010) · Blood · doi:10.1182/blood-2009-08-238543 · Cited by 114 · see citing works

Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA

Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H., Weller, M., & Pascolo, S. (2006) · European Journal of Immunology · doi:10.1002/eji.200635910 · Cited by 108 · see citing works

Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors.

Lu, D., Benjamin, R., Kim, M., Conry, R. M., & Curiel, D. (1994) · PubMed · Cited by 89 · see citing works

Innate recognition of viruses

de Sousa, E. M., & Reis, C. (2009) · ˜The œbiomedical & life sciences collection. · Cited by 89 · see citing works

FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines

Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Hüsemann, Y., Koslowski, M., Huber, C., Türeci, Ö., & Şahin, U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0291 · Cited by 78 · see citing works

Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins

Gulck, E. R. A. V. (2005) · Blood · doi:10.1182/blood-2005-01-0339 · Cited by 63 · see citing works

RNA Vaccines in Cancer Treatment

Bringmann, A., Held, S. A. E., Heine, A., & Brossart, P. (2010) · BioMed Research International · doi:10.1155/2010/623687 · Cited by 45 · see citing works

Role of Dendritic Cells in HIV-Immunotherapy

Gulck, E. R. V., Tendeloo, V. F. V., Berneman, Z. N., & Vanham, G. L. (2010) · Current HIV Research · doi:10.2174/157016210791208631 · Cited by 22 · see citing works

RNA immunization can protect mice against foot-and-mouth disease virus

Rodríguez‐Pulido, M., Sobrino, F., Borrego, B., & Sáiz, M. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.12.005 · Cited by 22 · see citing works

Untitled work

Hoerr, I. (2000) · doi:10.1002/1521-4141(200001)30:1

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · see citing works

mRNA vaccine for cancer immunotherapy

Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 947 · see citing works

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · see citing works

Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation

Miao, L., Li, L., Huang, Y., Delcassian, D., Chahal, J., Han, J., Shi, Y., Sadtler, K., Gao, W., Lin, J., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0247-3 · Cited by 723 · see citing works

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719 · see citing works

Advances in mRNA Vaccines for Infectious Diseases

Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 680 · see citing works

RNA-based therapeutics: an overview and prospectus

Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05075-2 · Cited by 658 · see citing works

mRNA vaccine delivery using lipid nanoparticles

Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works

Opportunities and Challenges in the Delivery of mRNA-Based Vaccines

Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584 · see citing works

CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery

Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560 · see citing works

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507 · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 428 · see citing works

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and <i>Toxoplasma gondii</i> challenges with a single dose

Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works

Materials for non-viral intracellular delivery of messenger RNA therapeutics

Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 400 · see citing works

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395 · see citing works

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376 · see citing works

Impact of lipid nanoparticle size on mRNA vaccine immunogenicity

Hassett, K. J., Higgins, J. S., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E. P., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 373 · see citing works

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368 · see citing works

Novel approaches for vaccine development

Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347 · see citing works

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works

A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines

Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338 · see citing works

Nucleic acid delivery for therapeutic applications

Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 339 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works

Principles for designing an optimal mRNA lipid nanoparticle vaccine

Kon, E., Elia, U., & Peer, D. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.09.016 · Cited by 269 · see citing works

From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases

Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 265 · see citing works

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

Kiaie, S. H., Zolbanin, N. M., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 261 · see citing works

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 242 · see citing works

Mechanism of action of mRNA-based vaccines

Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · see citing works

mRNA transcript therapy

Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228 · see citing works

Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging

Lindsay, K. E., Bhosle, S. M., Zurla, C., Beyersdorf, J., Rogers, K. A., Vanover, D., Xiao, P., Araínga, M., Shirreff, L. M., Pitard, B., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0378-3 · Cited by 218 · see citing works

Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design

Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208 · see citing works

Lipid-based mRNA vaccine delivery systems

Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 209 · see citing works

Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA

Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0095-2 · Cited by 206 · see citing works

Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways

Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201 · see citing works

Biomaterials for vaccine-based cancer immunotherapy

Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 201 · see citing works

Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo

Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 191 · see citing works

Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation

Coolen, A.-L., Lacroix, C., Mercier‐Gouy, P., Delaune, E. A., Monge, C., Exposito, J., & Verrier, B. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.019 · Cited by 192 · see citing works

RNA: The new revolution in nucleic acid vaccines

Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 187 · see citing works

Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine

Carlsson, L. G., Clarke, J. C., Yen, C. Y. T., Gregoire, F. M., Albery, T., Billger, M. A., Egnell, A., Gan, L., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 180 · see citing works

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines

Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 177 · see citing works

Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection

Lou, G., Anderluzzi, G., Schmidt, S., Woods, S., Gallorini, S., Brazzoli, M., Giusti, F., Ferlenghi, I., Johnson, R. N., Roberts, C. W., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.027 · Cited by 172 · see citing works

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works

Arginine‐Rich Peptide‐Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide

Udhayakumar, V. K., De Beuckelaer, A., McCaffrey, J., McCrudden, C. M., Kirschman, J. L., Vanover, D., Van Hoecke, L., Roose, K., Deswarte, K., De Geest, B. G., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201601412 · Cited by 169 · see citing works

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

Szebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., Barenholz, Y., Crommelin, D. J. A., & Dobrovolskaia, M. A. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01071-x · Cited by 168 · see citing works

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154 · see citing works

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153 · see citing works

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint

Granot-Matok, Y., & Peer, D. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.015 · Cited by 154 · see citing works

Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice

da Silva, J. R., Rodrigues, K. B., Pelegrin, G. F., Sales, N. S., Muramatsu, H., Silva, M. D. O., Porchia, B. F. M. M., Moreno, A. C. R., Aps, L. R. M. M., Venceslau-Carvalho, A. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3464 · Cited by 148 · see citing works

mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells

Bevers, S., Kooijmans, S. A. A., van de Velde, E., Evers, M. J. W., Seghers, S., Gitz-Francois, J. J., van Kronenburg, N. C. H., Fens, M. H. A. M., Mastrobattista, E., Hassler, L., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.007 · Cited by 146 · see citing works

Self-replicating alphavirus RNA vaccines

Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 137 · see citing works

Challenges and advances towards the rational design of mRNA vaccines

Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 134 · see citing works

Nanoplatforms for mRNA Therapeutics

Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · see citing works

Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells

Moignic, A. L., Malard, V., Benvegnu, T. J., Lemiègre, L., Berchel, M., Jaffrès, P., Baillou, C., Guillot‐Delost, M., Macedo, R., Rochefort, J., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.035 · Cited by 127 · see citing works

Biomedical applications of mRNA nanomedicine

Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125 · see citing works

Development and Delivery Systems of mRNA Vaccines

Liang, Y., Huang, L., & Liu, T. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.718753 · Cited by 125 · see citing works

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity

Phua, K. K. L., Staats, H. F., Leong, K. W., & Nair, S. K. (2014) · Scientific Reports · doi:10.1038/srep05128 · Cited by 123 · see citing works

mRNA-Based Vaccines

Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021) · Vaccines · doi:10.3390/vaccines9040390 · Cited by 127 · see citing works

Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses

De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122 · see citing works

Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon

Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121 · see citing works

mRNA therapeutics deliver a hopeful message

Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 120 · see citing works

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs

Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 120 · see citing works

mRNA vaccines for COVID-19 and diverse diseases

Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 117 · see citing works

mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond

Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 116 · see citing works

Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines

Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 109 · see citing works

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 111 · see citing works

Nanoparticle cancer vaccines: Design considerations and recent advances

Liu, J., Miao, L., Sui, J., Hao, Y., & Huang, G. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.10.006 · Cited by 108 · see citing works

Novel Platforms for the Development of a Universal Influenza Vaccine

Kumar, A., Meldgaard, T. S., & Bertholet, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00600 · Cited by 102 · see citing works

Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective

Ferhan, A. R., Park, S.-H., Park, H., Tae, H., Jackman, J. A., & Cho, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202203669 · Cited by 101 · see citing works

Messenger RNA-Based Vaccines Against Infectious Diseases

Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96 · see citing works

The ReNAissanCe of mRNA-based cancer therapy

Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95 · see citing works

mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo

Fornaguera, C., Guerra‐Rebollo, M., Lázaro, M. Á., Castells‐Sala, C., Meca‐Cortés, Ó., Ramos‐Pérez, V., Cascante, A., Rubio, N., Blanco, J., & Borrós, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800335 · Cited by 95 · see citing works

Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo

Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 96 · see citing works

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods &amp; Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94 · see citing works

Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections

Versteeg, L., Almutairi, M. M., Hotez, P. J., & Pollet, J. B. K. (2019) · Vaccines · doi:10.3390/vaccines7040122 · Cited by 93 · see citing works

Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants

Ong, G. H., Lian, B. S. X., Kawasaki, T., & Kawai, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.745016 · Cited by 95 · see citing works

Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses

Li, M., Li, Y., Peng, K., Wang, Y., Gong, T., Zhang, Z., He, Q., & Sun, X. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.10.019 · Cited by 91 · see citing works

Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity

Uchida, S., Kataoka, K., & Itaka, K. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7030137 · Cited by 88 · see citing works

mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases

Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 93 · see citing works

A new developing class of gene delivery: messenger RNA-based therapeutics

Zhao, M., Ahern, J. O., Lyu, J., Pierucci, L., Zhou, D., & Wang, W. (2017) · Biomaterials Science · doi:10.1039/c7bm00712d · Cited by 86 · see citing works

Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice

Mallory, K. L., Taylor, J. A., Zou, X., Waghela, I. N., Schneider, C. G., Sibilo, M. Q., Punde, N. M., Perazzo, L., Savransky, T., Sedegah, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00345-0 · Cited by 83 · see citing works

Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles

Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s39810 · Cited by 79 · see citing works

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79 · see citing works

Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines

Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 79 · see citing works

HIV mRNA Vaccines—Progress and Future Paths

Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 80 · see citing works

mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy

Sasaki, K., Sato, Y., Okuda, K., Iwakawa, K., & Harashima, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081572 · Cited by 78 · see citing works

Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates

Tan, L., Zheng, T., Li, M., Zhong, X., Tang, Y., Qin, M., & Sun, X. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00725-4 · Cited by 72 · see citing works

mRNA-based therapeutics–Advances and perspectives

Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 72 · see citing works

Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States

Montano, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.756633 · Cited by 70 · see citing works

mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles

Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 72 · see citing works

Messenger RNA (mRNA) nanoparticle tumour vaccination

Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70 · see citing works

Recent advances in mRNA vaccine delivery

Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 70 · see citing works

The Ugi Three‐Component Reaction; a Valuable Tool in Modern Organic Synthesis

Tripolitsiotis, N. P., Thomaidi, M., & Neochoritis, C. G. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202001157 · Cited by 69 · see citing works

Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

Wang, Z., Cui, K., Costabel, U., & Zhang, X. (2022) · Exploration · doi:10.1002/exp.20210082 · Cited by 66 · see citing works

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration

Van Hoecke, L., Roose, K., Ballegeer, M., Zhong, Z., Sanders, N. N., De Koker, S., Saelens, X., & Van Lint, S. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.09.004 · Cited by 55 · see citing works

Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon

Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121 · see citing works

Use of mRNA for vaccination or gene therapy: delivery route determines the verdict (P4316)

Pollard, C., Vandermeulen, G., Vanham, G. L., Grooten, J., Véronique Préat, A., & Koker, S. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.190.supp.45.6

Type 1 Interferon Restricts mRNA Vaccine Efficacy Through Suppression of Antigen Uptake in Conventional Dendritic Cells 2309444

Lobb, T. A., Dickson, A. M., Guo, W., Beeram, S., Carrero, J. A., Dalben, Y. R., DiPaolo, R. J., Alspach, E., Tse, L. V., & Ferris, S. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1548

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395 · see citing works